**Table S-2. Progression of clinical and biochemical parameters at 4 and 7 years following the initial visit in patients who developed and did not develop CVD**

|  |  |  |  |
| --- | --- | --- | --- |
|   | **Visit #1** | **Visit #2** | **Visit #3** |
|   | **NoCVD** | **CVD** | **NoCVD** | **CVD** | **NoCVD** | **CVD** |
|   | **Mean** | **Mean** | **Mean** | **Mean** | **Mean** | **Mean** |
| **Age (yrs)** | 47 | 46 | 51 | 50 | 54 | 53 |
| **Ht (cm)** | 172 | 167 | 172 | 167 | 172 | 167 |
| **Wt(kg)** | 83 | 78 | 84 | 78 | 81 | 78 |
| **BSA (m2)** | 1.99 | 1.90 | 2.09 | 1.90 | 1.97 | 1.90 |
| **BMI (kg/m2)** | 28.0 | 27.9 | 28.2 | 28.1 | 27.5 | 28.1 |
| **SBP (mmHg)** | 130 | 129 | 130 | 131 | 130 | 132 |
| **DBP (mmHg)** | 70 | 69 | 71 | 70 | 71 | 70 |
| **T-since-DM (yrs)** | 6.5 | 6.1 | 10.2 | 10.1 | 13.6 | 12.6 |
|   |   |   |   |   |   |   |
| **Biomarkers** |   |   |   |   |   |   |
| **Podocin** | .45 | 1.07 | 3.75 | 5.48 | 8.12 | 13.10 |
| **nephrin**  | 1.10 | 2.36 | 2.49 | 4.61 | 7.30 | 9.94 |
| **Triglycerides (mmol/L)** | 2.0 | 1.4 | 2.1 | 1.5 | 2.3 | 1.9 |
| **Total Cholesterol (mmol/L)** | 7.1 | 7.4 | 7.2 | 7.1 | 7.4 | 7.2 |
| **HDL (mmol/L)** | 1.2 | 1.0 | 1.4 | 1.0 | 1.4 | 1.2 |
| **LDL (mmol/L)** | 3.7 | 3.2 | 3.7 | 3.3 | 4.0 | 3.7 |
| **AER (mg/ mmol Cr)** | 0.96 | 1.03 | 11.0 | 17.1 | 98.6 | 84.1 |
| **serum Cr (mol/L)** | 97.2 | 97.2 | 132.6 | 159.1 | 176.8 | 282.9 |
| **eGFR** | 74.3 | 75.3 | 52.6 | 42.3 | 37.1 | 22.1 |
| **HbA1C (%)** | 7.4 | 7.3 | 7.5 | 7.6 | 8.0 | 8.1 |
|   |   |   |   |   |   |   |
| **Categorical** | **%** | **%** | **%** | **%** | **%** | **%** |
| **Male** | 86.0% | 87.5% | 86.0% | 87.5% | 86.0% | 87.5% |
| **Wt-Categ (0,1,2)** |   |   |   |   |   |   |
|  **Normal** | 16.0% | 25.9% | 16.0% | 19.6% | 14.0% | 19.6% |
|  **Overweight** | 54.0% | 48.1% | 62.0% | 50.0% | 72.0% | 50.0% |
|  **Obese** | 30.0% | 25.9% | 22.0% | 30.4% | 14.0% | 30.4% |
| **Smoking (0,1,2)** |   |   |   |   |   |   |
|  **Never** | 44.0% | 37.5% | 44.0% | 37.5% | 44.0% | 37.5% |
|  **Previous** | 20.0% | 12.5% | 10.0% | 12.5% | 34.0% | 12.5% |
|  **Current** | 36.0% | 50.0% | 46.0% | 50.0% | 22.0% | 50.0% |
| **Hypertension** | 60.0% | 48.2% | 50.0% | 64.3% | 66.0% | 64.3% |
| **Medication (Any)** | 88.0% | 83.9% | 100.0% | 94.6% | 100.0% | 96.4% |
| **Oral hypoglycemics** | 86.0% | 83.9% | 100.0% | 96.4% | 100.0% | 96.4% |
| **ACE Inhibitor** | 30.0% | 35.7% | 32.0% | 58.9% | 52.0% | 58.9% |
| **ARB** | 22.0% | 17.9% | 28.0% | 26.8% | 48.0% | 26.8% |
| **Statin** | 22.0% | 41.1% | 0.0% | 48.2% | 54.0% | 48.2% |